Actual Medicinal Product (AMP) Naramig 2.5mg tablets (Mawdsley-Brooks & Company Ltd)
This product can't be added to an MCA list.
Stability Information
(Some stability information inherited from generic)
- Stability
-
Lack of data and/or stability concerns exist. MCA use may be acceptable but is likely to be off-label and require mitigation measures. Keep medicines in MCAs for the shortest time necessary. Generally, up to 5 weeks maximum unless otherwise specified, or up to 8 weeks if the MCA is airtight (sealed). Consider the risk of potency loss or dose variability and monitor for changes in efficacy or adverse effects after MCA initiation.
- Notes
-
Store in airtight container.
- Provenance
-
Compatibility information derived from Naramig 2.5mg tablets (GlaxoSmithKline UK Ltd).
- Generic
- Naratriptan
- Formulation
- Naratriptan 2.5mg tablets
-
Naratriptan
-
Naratriptan 2.5mg tablets
-
Naramig 2.5mg tablets (Mawdsley-Brooks & Company Ltd)
-
-